Viewing Study NCT05853432


Ignite Creation Date: 2025-12-24 @ 9:45 PM
Ignite Modification Date: 2025-12-28 @ 4:27 PM
Study NCT ID: NCT05853432
Status: COMPLETED
Last Update Posted: 2023-05-10
First Post: 2023-05-02
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy
Sponsor: Novartis Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Outcomes Module Eligibility Module Contacts Locations Module